Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics Limited reported a significant increase in revenue from ordinary activities, doubling to $3,968,525 for the year ended 30 June 2025. Despite this growth, the company recorded a reduced loss of $10,430,424, down 16.8% from the previous year, attributed to cost-cutting measures such as headcount reduction and project reprioritization. The company’s net assets decreased, but cash reserves saw a notable increase, indicating improved liquidity. No dividends were declared for the current or previous financial year.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.76M
Learn more about CHM stock on TipRanks’ Stock Analysis page.